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DOI 10.1016/j.ccr.2010.05.015SUMMARYWe report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model resembling human
polycythemia vera (PV). The MPN is serially transplantable and we demonstrate that the hematopoietic
stem cell (HSC) compartment has the unique capacity for disease initiation but does not have a significant
selective competitive advantage over wild-type HSCs. In contrast, myeloid progenitor populations are
expanded and skewed toward the erythroid lineage, but cannot transplant the disease. Treatment with
a JAK2 kinase inhibitor ameliorated the MPN phenotype, but did not eliminate the disease-initiating popula-
tion. These findings provide insights into the consequences of JAK2 activation on HSC differentiation and
function and have the potential to inform therapeutic approaches to JAK2V617F-positive MPN.INTRODUCTION
The JAK2V617F mutation is the most common molecular
abnormality inBCR-ABL-negative MPN and is present in approx-
imately 95% of patients with PV and in approximately 50% of
patients with essential thrombocythemia (ET) and primary myelo-
fibrosis (PMF) (Baxter et al., 2005). JAK2V617F is present at low
frequency in other myeloid malignancies and is not observed at
all in lymphoid neoplasms (Steensma et al., 2005; Levine et al.,
2005a). This acquired point mutation in the JAK2 gene results
in a valine to phenylalanine substitution at position 617 and
constitutive activation of JAK2 kinase signaling (James et al.,
2005; Kralovics et al., 2005; Baxter et al., 2005; Levine et al.,Significance
The JAK2V617Fmutation is a promising candidate for molecul
clinical trials have called into question the capacity of these com
MPN. Determining the effect of JAK2 inhibitors on the dis
JAK2V617F allele is expressed at physiological levels in hema
model demonstrates that JAK2V617F causes expansion of ery
initiate disease in a transplanted mouse. We further demonstra
tive therapy of JAK2V617F-mediated MPN, is resistant to trea
584 Cancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc.2005b). Overexpression of JAK2V617F confers interleukin-3
(IL-3) independence to Ba/F3 cells that coexpress a homodimeric
type I cytokine receptor, such as the erythropoietin receptor
(EpoR) (Lu et al., 2005). Transplantation of JAK2V617F-overex-
pressing hematopoietic cells into mice is sufficient to recapitulate
a PV disease phenotype (Wernig et al., 2006; Lacout et al., 2006;
Zaleskas et al., 2006). In aggregate, JAK2 therefore represents an
excellent therapeutic target in MPN patients.
So that MPNcould be cured in humanpatients, itmaybe neces-
sary to eradicate all JAK2V617Fmutated hematopoietic cells that
have the capacity to self-renew and thus maintain disease. In this
context, it is therefore imperative to understand the precise role
and function of the JAK2V617Fallele as it relates to hematopoieticarly targeted therapy in MPN. Early data from JAK2 inhibitor
pounds to alter the natural history of JAK2V617F-mediated
ease-initiating population requires a model in which the
topoietic stem and progenitor cells, as it is in humans. Our
throid progenitors but that only the HSC compartment can
te that the HSC compartment, the definitive target for cura-
tment with a JAK2 inhibitor.
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Jak2V617F Knockin Murine MPN Modelstem and multipotent progenitor cells (HSPCs). In MPN patients,
JAK2V617F is detectable in CD34+ CD38 hematopoietic stem
cells (HSCs) (Jamieson et al., 2006) and in all mature cell lineages
(Ishii et al., 2006; Delhommeau et al., 2007). However, detailed
functional characterization of JAK2V617F HSPCs has been
limited in existing retroviral and transgenic murine models (Wernig
et al., 2006; Lacout et al., 2006; Zaleskas et al., 2006; Tiedt et al.,
2008; Xing et al., 2008; Shide et al., 2008) and has been described
only in the nonobese diabetic-severe combined immunodeficient
(NOD/SCID) murine model to date (James et al., 2008). Although
the retroviral JAK2V617F model has been informative (Wernig
et al., 2006; Lacout et al., 2006; Zaleskas et al., 2006), it is subject
to the problems inherent to retroviral-mediated transduction,
including the identity of the transduced cells, with preferential
transduction of mitotic progenitor cells relative to quiescent
long-term HSCs and the nonphysiologic level of oncogene
expression. These factors may ultimately affect the resultant bio-
logical and phenotypic outcome in these models (Ren, 2004).
Transgenic model systems also have nonphysiologic expression
of the oncogene resulting from increased copy number and the
use of exogenous promoters.
Over the course of a decade of treating chronic myelogenous
leukemia (CML) with imatinib, it has become evident that cure is
difficult to achieve as a consequence of a reservoir of disease-
initiating cells contained within the quiescent HSC compartment
(Holyoake et al., 1999; Graham et al., 2002; Michor et al., 2005).
Furthermore, preliminary results from small molecule JAK2
kinase inhibitor trials suggest that curative therapy of BCR-
ABL-negative MPN may prove even more difficult (Pardanani
et al., 2009; Verstovsek et al., 2009). An accurate knowledge of
the early changes that occur in the HSPC compartment directly
as a result of acquisition of the JAK2V617F mutation is therefore
critical in determining the curative potential of therapies that
target this molecular event.
We describe a Jak2V617F knockin model in which expression
of Jak2V617F is under the control of the endogenous murine
Jak2 promoter; we provide detailed analysis of the effects of
the Jak2V617F allele on hematopoietic stem and progenitor
cells; and we evaluate the efficacy of a small molecule JAK2
inhibitor in vivo.
RESULTS
Expression of Jak2V617F from Its Endogenous
Promoter Results in a Lethal MPN Resembling
Human Polycythemia Vera
We generated a Jak2V617F conditional knockin allele by gene
targeting in mouse embryonic stem cells (Figure 1A). The result-
ing chimeric animals were crossed with wild-type (WT) C57Bl/6
mice to generate floxed heterozygous Jak2V617F mice. Floxed
heterozygous Jak2V617F animals were then crossed with
E2ACre transgenic mice to induce germline Jak2V617F expres-
sion during early mouse embryogenesis (Lakso et al., 1996).
Inversion of the floxed knockin allele and excision of the wild-
type exon were confirmed by PCR (Figure 1B), and expression
of the G1849T mutation (that results in a valine to phenylalanine
substitution at amino acid position 617, Jak2V617F) was
confirmed by cDNA sequencing (Figure 1C). These heterozy-
gous Jak2V617F germline expressing animals (Jak2+/VF) devel-oped a lethal MPN that was 100% penetrant with a median
survival of 146 days (Figure 1D). The MPN was characterized
by an elevated hematocrit (HCT) (Figure 1F), splenomegaly
(Figure 1G; Figure S1A available online), and prominent splenic
extramedullary erythropoiesis (Figure 1E). Flow-cytometric anal-
ysis showed increased CD71+ Ter119+ erythroid precursors in
Jak2+/VF bone marrow (BM) (Figure S1B) and spleen (Figure 1H).
Histopathology demonstrated marked erythroid and mild mega-
karyocytic hyperplasia within the Jak2+/VF splenic red pulp with
overall effacement of the normal splenic architecture (Figure 1I).
The Jak2+/VF BM showed a milder increase in erythroid elements
compared to the spleen but demonstrated megakaryocytes with
atypical nuclear features and prominent emperipolesis (Fig-
ure 1I). CD41+ cells were increased in Jak2+/VF BM (p = 0.05),
platelet counts were not increased, and no differences were
observed in megakaryocyte ploidy between Jak2+/VF and
Jak2+/+ mice (Figures S1C–S1E). WBC counts were increased
in Jak2+/VF mice (p < 0.0001) although we did not observe an
increase in Mac1+Gr1+ or Mac1+ cells relative to total Jak2+/VF
BM cells (Figures S1F–S1H). Reticulin fibrosis was absent in both
Jak2+/VF BM and spleen, even in mice that were 6 months old
(Figure 1J), and the development of acute leukemia was not
observed in any animals. In aggregate, these findings demon-
strate that Jak2+/VF knockin mice develop a MPN reminiscent
of human PV with a short disease latency and reduced survival.
Erythroid Skewing in the Myeloid Progenitor
Compartment of Jak2V617F Mice
Having demonstrated that Jak2+/VF mice developed elevated
HCT and expanded erythroid precursor cells, we undertook a
quantitative evaluation of the BM myeloid progenitor com-
partment of Jak2+/VF or Jak2+/+ mice. We found that immuno-
phenotypically defined myeloid progenitor cells (Lineagelow
Sca1cKithigh) were increased in Jak2+/VF mice (Figure S2A,
p = 0.002) mainly as a result of expansion of the megakaryo-
cytic/erythroid progenitor (MEP) population within this compart-
ment (Figure 2C; Figures S2B and S2C). The ratio of common
myeloid progenitor (CMP) and granulocyte/macrophage progen-
itors (GMP) cells to total BM cells was unchanged when
comparing Jak2+/VF and Jak2+/+ mice (Figures S2D and S2E).
We then performed a more detailed examination of megakaryo-
cytic and erythroid progenitor populations via the additional
markers CD150, CD41, and CD105 (Pronk et al., 2007). These
studies showed an increase in lineagelowcKithigh
CD150+CD41CD105+ Pre-CFU-E cells (that have only erythroid
lineage potential), relative to lineagelowcKithighCD150+CD41
CD105 Pre-MegE cells (that have mixed erythroid/megakaryo-
cytic potential) and lineagelowcKithighCD41+ MkP cells (that are
lineage restricted to a mature megakaryocytic fate) (Figures
2A, 2B, and 2D), in Jak2+/VF mice compared with Jak2+/+ mice.
The Jak2+/VF expanded CD71+ Ter119+ proerythroblast popula-
tion is contained within the CD150, CD105+ compartment.
These results demonstrate that Jak2V617F causes marked
erythroid skewing of progenitor populations: disproportionately
increasing MEP cells over other myeloid progenitors and
increasing Pre-CFU-E cells relative to megakaryocyte pro-
genitors.
One of the pathognomonic features of PV is hypersensitivity
of erythroid progenitors to erythropoietin (EPO) and growthCancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc. 585
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Figure 1. Physiological Jak2V617F Expression Causes a Lethal MPN Resembling PV
(A) Targeting vector schema for the Jak2V617F conditional knockin mouse.
(B) PCR analysis of tail DNA from Jak2+/+, Jak2+/Fl, and Jak2+/VF mice for genotyping (Geno), detection of floxed band (Flox), and detection of excised band (Exc);
(Fl = Floxed).
(C) Jak2 sequencing analysis of unfractionated BM cells from Jak2+/+ and Jak2+/VF mice.
(D) Kaplan-Meier analysis of a cohort of Jak2+/VF mice (n = 17) and littermate controls (n = 13).
(E) Composite data from age-matched littermates of Jak2+/+ and Jak2+/VF mice (unpaired two-tailed t test; mean ± SEM; n = 4 in each group) demonstrating
increased in CD71+, Ter119+ erythroid precursors in Jak2+/VF spleens.
(F) Hematocrits of age-matched littermate Jak2+/+ and Jak2+/VF mice aged 4–14 weeks (mean ± SEM; n = 16 in each group).
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Jak2V617F Knockin Murine MPN Modelwith a low plating efficiency even in the absence of EPO. We
plated unfractionated BM cells or highly purified MEP cells
derived from Jak2+/VF or Jak2+/+ mice in media containing
growth factors supplemented with decreasing concentrations
of EPO. We observed EPO hypersensitivity in both Jak2+/VF
unfractionated BM and Jak2+/VF MEPs, although we did not
observe endogenous erythroid colony formation (Figures 2E
and 2F). Consistent with this, we also found that Jak2+/VF MEP
cells demonstrated increased phospho-Stat5 signaling in
response to stimulation with EPO and interleukin-3 (IL3) as
compared with Jak2+/+ MEP cells (Figure S2F).
The Jak2V617F MPN-Initiating Population Is Contained
within the HSC-Enriched LSK Population
Existing murine MPN models have generally demonstrated poor
transplantability of the primary disease (Chan et al., 2004, 2009;
Braun et al., 2004; Lee et al., 2007), limiting the evaluation of the
disease-initiating population in these models. To assess the
transplantability of Jak2V617F-evoked MPN, we first trans-
planted unfractionated BM cells from diseased Jak2+/VF mice
into lethally or sublethally irradiated littermate recipients and
unfractionated spleen cells from diseased Jak2+/VF mice into
lethally irradiated littermate recipients. In all cases, a MPN devel-
oped in secondary recipients, characterized by elevated HCT as
early as 4 weeks posttransplantation (Figure 3A) and a median
survival of 342 days in this mixed group of transplants.
We next sought to identify the hematopoietic developmental
stage that contains the disease-initiating cell. Highly purified
BM LSK, MEP, or GMP cell populations from Jak2+/VF and
Jak2+/+ animals, respectively, were transplanted into lethally
irradiated congenic secondary recipients and full donor engraft-
ment was confirmed in all recipients. Recipient mice that
received Jak2+/VF LSK cells developed a MPN that was similar
to that which developed in primary mice, characterized by
elevated HCT (Figure 3B), increased WBC and platelet counts
(Figures S3A and S3B), prominent extramedullary erythropoiesis
(Figure 3C), increased MEP cells (Figure S3C), and erythroid
and megakaryocytic hyperplasia in the BM (Figures 3D and
3E). In contrast, animals that received either the Jak2+/VF MEP
or Jak2+/VF GMP-committed progenitor populations did not
develop MPN with >6 months of followup (Figures 3B, 3F, and
3G). Furthermore, lethally irradiated tertiary recipients of unfrac-
tionated BM from mice that were transplanted with Jak2+/VF
LSK cells 6 months earlier also developed elevated HCT
(Figure 3B), and upon sacrifice, histopathologic evidence of
MPN was evident, demonstrating that the disease is serially
transplantable (Figures S3D and S3E). These experiments
demonstrate that Jak2V617F-expressing LSK cells, but not(G) Photograph of spleens from Jak2+/+ (upper; weight = 0.08 G) and Jak2+/VF (
mouse.
(H) Representative flow-cytometric analysis of single cell suspensions of spleen fr
CD71+ Ter119+ cells (subpopulations I and II) in Jak2+/VF mice.
(I) Histopathologic H&E sections of bone marrow (BM) and spleen (SPL) from
hyperplasia with clustering and emperipolesis in Jak2+/VF BM and marked ery
when compared with unremarkable BM and SPL from Jak2+/+ controls (BM, firs
50 mM]; SPL, third column [scale bars represent 500 mM], fourth column [scale b
(J) Histopathologic reticulin sections of bone marrow (BM) and spleen (SPL) from
fibrosis (BM, first and second panels [scale bars represent 250 mM]; SPL, third a
See also Figure S1.committed myeloid progenitors, are able to initiate and maintain
the MPN in vivo.
Jak2V617F Directs Differentiation within the LSK
Compartment but Has Otherwise Modest Effects
on LSK Cells
We observe that the MPN-initiating population is contained
within the LSK compartment, and the JAK2V617F mutation
has been identified in HSCs from human MPN patients (Jamie-
son et al., 2006). Based on these insights, we further assessed
the LSK compartment that contains long-term (LT) and short-
term (ST) HSCs (Spangrude et al., 1988), as well as multipotent
progenitor cells (MPPs). We found no significant quantitative
differences between Jak2+/VF and Jak2+/+ LSK cells (Figure S4A).
Similarly, we did not observe quantitative differences in immuno-
phenotyically defined LT-HSCs (CD150+CD48 LSKs) (Kiel et al.,
2005) when comparing Jak2+/VF and Jak2+/+ BM (Figure S4B). In
an assessment of the functional effects of the Jak2V617F muta-
tion in LSK cells, we did not observe any significant differences
between Jak2+/+ and Jak2+/VF LSK cells with regard to cell cycle
status (Figure 4A).
These observations suggested that JAK-STAT signal trans-
duction might not be differentially activated between Jak2+/VF
and Jak2+/+ LSK cells. To assess this possibility, we used flow
cytometry to assess phospho-Stat5 levels within Jak2+/VF and
Jak2+/+ LSK cells via a phospho-specific Stat5 antibody (Fig-
ure 4B). Consistent with our colony-forming cell (CFC) data
(described above), we observed no difference in basal Stat5
phosphorylation signaling after serum starvation between
Jak2+/VF and Jak2+/+ LSK cells. Similarly, there was no statisti-
cally significant difference in Stat5 activation between these
populations in response to stimulation with EPO plus IL3
(Figure 4C). We also assessed Stat5 activation in Jak2+/VF or
Jak2+/+ LSK cells in response to low-dose EPO and IL3 stimula-
tion and obtained similar results to those obtained at the higher
doses (Figure S4C). As expected, Stat5 activation after cytokine
stimulation was inhibited by in vitro treatment with the JAK2 inhib-
itor TG101348 (300 nM), although phospho-Stat5 did not return
to basal levels under these experimental conditions (Figure 4B).
To further explore the functional consequences of Jak2V617F
expression in the LSK compartment, and in view of the recently
described role of JAK2 as an epigenetic regulator through phos-
phorylation of Tyr 41 (Y41) on histone H3 (Dawson et al., 2009),
we analyzed Jak2+/VF or Jak2+/+ LSK cells by gene expression
profiling. In a supervised analysis of Jak2+/VF versus Jak2+/+
LSK cells, no individual genes were significantly differentially
expressed between the two states (FDR < 0.05). Given that we
observed expansion and erythroid skewing of the myeloidlower; weight = 3.1 G) mice demonstrating marked splenomegaly in Jak2+/VF
om age-matched littermate Jak2+/+ and Jak2+/VF mice, indicating expansion of
representative Jak2+/+ and Jak2+/VF mice demonstrating megakaryocyte
throid hyperplasia with complete effacement of white pulp in Jak2+/VF SPL
t column [scale bars represent 250 mM], second column [scale bars represent
ars represent 125 mM]).
representative Jak2+/+ and Jak2+/VF mice demonstrating absence of reticulin
nd fourth panels [scale bars represent 250 mM].
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Figure 2. Erythroid Skewing in the Myeloid Progenitor Compartment of Jak2V617F Mice
(A and B) Multiparameter flow cytometry of Jak2+/+ and Jak2+/VF BM. Representative contour plots indicating LK subsets (MkPs, GMPs, Pre Meg-Es, and Pre
CFU-Es) are shown. All values are mean frequency of total BM cells. Representative data from one of two independent experiments (n = 4 in each group).
(C) Composite data from age-matched littermates of Jak2+/+ and Jak2+/VF mice demonstrating significantly increased numbers of MEP cells in Jak2+/VF BM over
Jak2+/+ BM (unpaired two-tailed t test; mean ± SEM; n = 4 in each group).
(D) Composite data from age-matched littermates of Jak2+/+ and Jak2+/VF mice demonstrating significantly increased numbers of Pre CFU-E cells in Jak2+/VF BM
over Jak2+/+ BM (unpaired two-tailed t test; mean ± SEM; n = 4 in each group).
(E and F) Unfractionated BM and MEP cells from Jak2+/+ and Jak2+/VF mice were plated and scored for BFU-E colony formation 7–10 days later. Results are the
average of two independent experiments performed in duplicate (unpaired two-tailed t test; mean ± SEM).
See also Figure S2.
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Jak2V617F Knockin Murine MPN Modelprogenitor compartment of Jak2+/VF mice and that recipients
of Jak2+/VF BM developed elevated HCT as soon as 3 weeks
posttransplantation (Figures 3A and 3B), we used gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) to
compare murine myeloid progenitor signatures in Jak2+/VF or
Jak2+/+ LSK cells. We observed that MEP, CMP, and GMP differ-
entiation signatures (Krivtsov et al., 2006) were significantly588 Cancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc.enriched in Jak2+/VF LSK cells (Table S1, Figure S4D). We also
found significant enrichment of erythroid and megakaryocytic
progenitor differentiation signatures (Pronk et al., 2007) in
Jak2+/VF LSK cells (Table S1). These findings indicate that
although the Jak2V617F mutation does not expand LSK cell
numbers, it directs hematopoietic differentiation within the LSK
compartment.
Figure 3. The Jak2V617F MPN-Initiating Population Is Contained within the LSK Population
(A) HCT of lethally (Lethal) or sublethally (Sublethal) irradiated littermate secondary recipients of unfractionated BM or SPL cells from diseased Jak2+/VF mice
measured 4–14 weeks posttransplantation (mean ± SEM; n = 3 in each group).
(B) HCT of lethally irradiated secondary (2) recipients of purified Jak2+/VF BM subpopulations (LSKs, MEPs, and GMPs) and corresponding Jak2+/+ BM subpop-
ulations and of lethally irradiated tertiary (3) recipients of unfractionated BM, measured 2–21 weeks posttransplantation (mean ± SEM; n = 5 in each group).
(C) Composite data from secondary recipients of purified Jak2+/VF BM subpopulations (LSKs, MEPs, and GMPs), demonstrating increased CD71+, Ter119+
erythroid precursors in spleens of secondary recipients of purified Jak2+/VF LSK cells (unpaired two-tailed t test; mean ± SEM; n = 3 in each group).
(D–G) Histopathologic H&E sections of BM from representative secondary recipients of purified Jak2+/+ and Jak2+/VF LSK cells, Jak2+/VF MEP cells, and Jak2+/VF
GMP cells, demonstrating erythroid hyperplasia, increased megakaryocytes in clusters with large forms, and emperipoliesis in Jak2+/VF LSK; slight increase in
megakaryocytes in Jak2+/VF MEP and mild myeloid hyperplasia in Jak2+/VF GMP as compared with unremarkable BM from Jak2+/+ LSK (BM [scale bars represent
250 mM]).
See also Figure S3.
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Figure 4. Jak2V617F Has Modest Effects in the LSK Compartment and Does Not Confer a Significant Competitive Advantage to LSK Cells
(A) Representative multiparameter flow cytometry of LSK populations in Jak2+/+ and Jak2+/VF mice demonstrating no significant differences in cell numbers in
different phases of cell cycle. All values are mean frequency of total LSK cells. Representative data from one of two independent experiments (n = 4 in each group).
(B) Representative flow cytometric analysis of levels of phospho-STAT5 (p-STAT5) in LSK cells from Jak2+/+ and Jak2+/VF littermate controls, after serum
starvation (starve) or stimulation with EPO (3 U/mL) and IL3 (10 ng/mL) for 10 min, in the absence (EPO/IL3) or presence of the JAK2 inhibitor TG101348
(EPO/IL3/JAK2i). Representative data from one of three independent experiments.
(C) Composite data from Jak2+/+ and Jak2+/VF LSK cells purified from primary mice (unpaired two-tailed t test; mean ± SEM), demonstrating no significant
difference in phospho-STAT5 activation after stimulation with EPO/IL3 (n = 4 in each group).
(D) Jak2+/VF(VF) to Jak2+/+ (WT) chimerism ratios assessed in BM LSK compartment from lethally irradiated secondary recipients of Jak2+/VF and Jak2+/+ LSK
cells in 75:25, 50:50, and 25:75 ratios measured 16 weeks posttransplantation (mean ± SEM; n = 4 in each group).
(E) Jak2+/VF (VF) to Jak2+/+ (WT) myeloid chimerism ratios assessed in peripheral blood (PB) from lethally irradiated secondary recipients of Jak2+/VF and Jak2+/+
LSK cells in 75:25, 50:50, and 25:75 ratios measured 5–16 weeks posttransplantation (mean ± SEM; n = 6 in each group).
See also Figure S4 and Table S1.
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Advantage to LSK Cells
Our observations on LSK cell number and gene expression, cell
cycle, and Stat5 signaling indicate that in aggregate, physiologic
expression of the Jak2V617F allele has quite modest effects on
the LSK compartment.590 Cancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc.To further assess LSK function and to determine whether the
Jak2V617F allele conferred a selective advantage to Jak2+/VF
LSK cells when compared with Jak2+/+ LSK cells, we performed
competitive transplantation experiments. We transplanted LSK
cells into lethally irradiated congenic recipients by using the
following Jak2+/VF to Jak2+/+ ratios: 75:25, 50:50, or 25:75 in
Cancer Cell
Jak2V617F Knockin Murine MPN Modelcombination with 250,000 WT supportive BM cells. All recipient
groups developed HCT > 55% that was sustained over 16 weeks,
all developed the same degree of expansion of CD71+ Ter119+
cells in the spleen, and all demonstrated the same degree of
splenomegaly (Figures S4E–S4G). LSK cell chimerism in the
BM at 16 weeks showed that the ratios of Jak2+/VF to Jak2+/+
LSK cells were mildly increased from the input Jak2+/VF to
Jak2+/+ ratios in all groups (Figure 4D). Peripheral blood myeloid
chimerism demonstrated similar results to LSK chimerism
(Figure 4E) and there was no significant difference in the
percentage of peripheral blood Mac1+ Gr1+ myeloid cells
between the groups (Figure S4H). These data demonstrate that
Jak2V617F confers, at most, a minor selective competitive
advantage on the HSC-enriched LSK population and that the
presence of even a minority of Jak2+/VF LSK cells in the BM is
sufficient to cause a marked expansion of erythroid precursors
in the spleen and the development of a PV phenotype.
Inhibiting JAK2 Kinase Does Not Eradicate
the MPN-Initiating Population
Together, these data indicate that Jak2V617F has nominal
effects on the size or function of the LSK compartment. A clini-
cally relevant prediction of these observations is that inhibition
of Jak2V617F might be expected to have minimal effects on
this compartment. If this hypothesis were correct, it could have
implications for this population as a resistant reservoir of MPN-
initiating cells—and for the efficacy of JAK2 inhibitors as curative
rather than remitting therapy.
To first evaluate whether Jak2+/VF mice respond to treatment
with a JAK2 inhibitor, we treated primary mice with the JAK2
kinase inhibitor TG101348 (Wernig et al., 2008) or vehicle for 6
weeks by oral gavage (60 mg/kg twice daily). Primary Jak2+/VF
mice responded to treatment with a statistically significant
reduction in spleen size (Figure 5A) and histopathological
improvement of the erythroid hyperplasia in the BM and spleen
(Figures 5B and 5C), compared with mice treated with vehicle.
HCT remained elevated in treated mice, possibly a reflection of
the long life span of red blood cells. We also treated lethally irra-
diated congenic tertiary recipients of unfractionated Jak2+/VF BM
with TG101348 for 6 weeks by oral gavage (60 mg/kg twice
daily). Tertiary recipients also responded to treatment and in
addition to a statistically significant reduction in spleen size (Fig-
ure S4I), decreased erythroid precursors were observed in the
spleens of TG101348-treated mice, compared with tertiary
recipient mice treated with vehicle (Figure 5D).
To assess the effect of Jak2 inhibition on the MPN-initiating
cell population, we performed serial transplantation experiments
(see Figure 5F for schema). We first purified LSK cells from
primary Jak2+/VF mice that had been treated with TG101348 or
vehicle for 6 weeks by oral gavage (60 mg/kg twice daily) and
transplanted equal numbers of cells into lethally irradiated con-
genic secondary recipients. Three weeks later, blood counts
demonstrated full hematopoietic reconstitution, with elevated
HCT in all secondary recipient mice (Figure 5E), demonstrating
that the MPN-initiating population was not eliminated in primary
treated mice. To investigate whether treatment for a longer
duration could eradicate the disease-initiating population,
TG101348 treatment was initiated in secondary recipients of
LSK cells from a TG101348-treated primary mouse and vehicletreatment was initiated in secondary recipients of LSK cells
from a vehicle-treated primary mouse. Both the treatment and
vehicle groups showed sustained elevation in HCT (Figure 5E).
After 10 weeks of treatment with TG101348, unfractionated
BM was then transplanted from treated secondary recipients
into lethally irradiated congenic tertiary recipients, and at 3 weeks
posttransplantation, these tertiary recipients also demonstrated
elevated HCT (Figure 5E), indicating that the MPN-initiating
population was not eliminated in secondary treated mice.
In aggregate, these data indicate that although the JAK2
kinase inhibitor TG101348 demonstrated therapeutic efficacy
against serially transplanted Jak2V617F-evoked MPN with
regard to reduction in spleen size and in erythroid precursor
cell number, treatment with the drug did not eliminate the
MPN-initiating population in vivo.DISCUSSION
Eradicating the disease-initiating cells within a tumor is the
definitive goal of curative cancer therapy. In murine models of
leukemia, the cell populations that possess the capacity to
initiate disease vary depending on the oncogene driving the
leukemia (Cleary, 2009). In general, murine MPN models have
been limited in their ability to address questions pertaining to
the MPN-initiating cell population because of poor transplant-
ability of the primary disease (Chan et al., 2004, 2009; Braun
et al., 2004; Lee et al., 2007). We report a murine knockin model
in which Jak2V617F is expressed from its endogenous promoter
and in which the MPN that arises is serially transplantable. We
demonstrate the presence of at least two distinct cellular
subfractions that are essential for MPN pathogenesis. The
Jak2V617F LSK population is enriched for disease-initiating
activity but has few phenotypic attributes that distinguish it
from a wild-type LSK population. In contrast, Jak2V617F MEP
cells are expanded in number and drive the disease phenotype
in vivo but do not transplant the MPN. Concordantly, treatment
with a JAK2 inhibitor attenuates the disease phenotype but the
MPN-initiating population retains its ability to reconstitute
disease.
The Jak2V617F knockin murine model we report was engi-
neered to faithfully reproduce the human situation, and the
murine phenotype closely recapitulates many of the features of
human PV. Jak2+/VF MEPs exhibit hypersensitivity to EPO stim-
ulation as manifested by enhanced growth of erythroid colonies
in methylcellulose media supplemented with low-dose EPO but
do not demonstrate endogenous erythroid colony formation.
These results are consistent with in vitro studies of primary
human PV patient samples (Jamieson et al., 2006; Dupont
et al., 2007). The absence of reticulin fibrosis in this model is
compatible with the existence of strain-specific and microenvi-
ronmental modifiers of fibrosis. This phenotype is more promi-
nent in Balb/c mice in the retroviral JAK2V617F model (Wernig
et al., 2006) and rapidly progressive BM fibrosis is seen in the
TEL-JAK2 NOD/SCID model, in which JAK2 is activated as
a result of a chromosomal translocation (Kennedy et al., 2006).
Our transplantation experiments demonstrate that the develop-
ment of Jak2V617F-evoked MPN is cell autonomous, consistent
with the finding that the JAK2V617Fmutation is not detectable inCancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc. 591
Figure 5. JAK2 Kinase Inhibition Does Not Eradicate the MPN-Initiating Population
(A) Composite data from primary Jak2+/VF age-matched littermates treated with vehicle or the JAK2 inhibitor TG101348 for 6 weeks, demonstrating reduced
spleen weight in mice treated with TG101348 as compared with those treated with vehicle (unpaired two-tailed t test; mean ± SEM; n = 3 in each group).
(B and C) Histopathologic H&E sections of spleen from representative primary Jak2+/VF mice treated with vehicle or JAK2 inhibitor TG101348 for 6 weeks, demon-
strating complete effacement of normal splenic architecture in vehicle-treated mice and improvement toward normal in TG101348-treated mice (SPL [scale bars
represent 250 mM]).
(D) Composite data from tertiary Jak2+/VF recipients treated with vehicle or TG101348 for 6 weeks and from untreated Jak2+/+ controls, demonstrating reduced
splenic cellularity and reduced number of CD71+ Ter119+ erythroid precursor cells in mice treated with TG101348 (mean ± SEM; n = 4 in each group; Tot, total;
Ery, erythroid).
(E) HCTs of lethally irradiated secondary recipients of purified Jak2+/VF LSKs from mice treated with vehicle or JAK2 inhibitor TG101348 for 6 weeks pretransplant
and resumed 3 weeks posttransplantation. HCTs of lethally irradiated secondary recipients of purified Jak2+/+ control LSKs, measured 2–10 weeks post-
transplantation, also shown.
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2008; Mercier et al., 2009).
Our preliminary observations suggest that lethality of the MPN
in this model may have been related to thrombotic events.
Animals died suddenly, precluding detailed histopathologic
analysis, but among a small cohort of animals who had limited
necropsy, gangrenous bowel was observed that would be
consistent with thrombosis. We also note that thrombotic events
were not observed in retroviral transduction or transgenic
JAK2V617F models (Wernig et al., 2006; Lacout et al., 2006;
Zaleskas et al., 2006; Tiedt et al., 2008; Xing et al., 2008; Shide
et al., 2008) and that cardiac thrombosis was indicated as a
cause of death in homozygous Jak2V617F-expressing animals
in the recently published conditional knockin model of Akada
et al. (2010). Collectively, these data suggest the possibility
that physiologic expression of the Jak2V617F allele from the
endogenous Jak2 promoter may enable preclinical studies of
thrombosis in MPN.
JAK2 was recently identified to have a previously unrecog-
nized nuclear role, directly phosphorylating Tyr 41 (Y41) on
histone H3 and preventing binding of the transcriptional
repressor heterochromatin protein 1f (HP1f) to H3 (Dawson
et al., 2009). We did not find any significantly differentially
expressed genes within the LSK compartment of Jak2+/VF
mice, indicating that endogenous heterozygous Jak2V617F
expression has minimal effects on global HSPC gene expres-
sion. Microarray profiling of Jak2+/VF LSKs demonstrated a
robust enrichment of myeloid progenitor differentiation signa-
tures including those derived from MEP (Krivtsov et al., 2006)
and Pre-CFU-E cells (Pronk et al., 2007), respectively, indicating
that Jak2V617F instructs HSC differentiation, consistent with
what has been observed in vitro in HSCs from PV patients
(Jamieson et al., 2006). Our demonstration that Jak2+/VF LSK
cells have little selective advantage over Jak2+/+ LSK cells in
competitive transplant experiments are in keeping with NOD/
SCID models of JAK2V617F PV, in which the majority of SCID
repopulating cells (SRCs) are wild-type cells and transformed
SRCs have no proliferative advantage over normal SRCs (James
et al., 2008). Moreover, human patients with ET, who are hetero-
zygous for the JAK2V617F mutation, can maintain a stable
JAK2V617F clone over years (Gale et al., 2007).
Because we could not generate homozygote Jak2V617F-
expressing mice in this model, we were unable to address the
impact of allelic dosage on disease phenotype. However, given
that the phenotype of heterozygote Jak2V617F-expressing
mice is more consistent with PV than ET, it may be that additional
somatic mutations and/or host modifiers (Pardanani et al., 2008)
contribute to MPN phenotypic pleiotropy. In support of this
hypothesis, another conditional Jak2V617F knockin model was
published during the course of the preparation of this manu-
script, in which both heterozygote and homozygote mice
demonstrated a similar PV phenotype, with more severe disease
observed in the homozygote animals (Akada et al., 2010). We
observe minor phenotypic differences between the models,
including the development of thrombocytosis, mild splenicHCTs of tertiary recipients of unfractionated Jak2+/VF BM from treated secondar
SEM; n = 3 in each group for secondary recipients; n = 6 for tertiary recipients).
(F) Schema outlining schedule for primary, secondary, and tertiary Jak2+/VF micereticulin fibrosis, and expansion of the LSK population that we
did not see in heterozygote Jak2V617F-expressing mice in our
study. These differences may be explained in part by the use
of Mx1Cre recombinase by Akada et al. (2010), requiring the
administration of polyinosinic-polycytidylic acid (pIpC) for induc-
tion, because it has recently been demonstrated that interferon-
f can cause proliferation of HSCs in vivo (Essers et al., 2009;
Sato et al., 2009).
JAK2 small molecule inhibitors are currently in early phase
clinical trials in patients with advanced myelofibrosis (Pardanani
et al., 2009; Verstovsek et al., 2009). Although treated patients
have generally been noted to experience rapid, marked
decreases in spleen size and hematological responses, these
findings have not been consistently associated with a reduction
in JAK2V617F allelic burden (Verstovsek et al., 2008). Further-
more, patients without JAK2 mutations who were enrolled in
these trials have also demonstrated clinical responses, indi-
cating that clonal JAK2V617F-positive disease is not being
selectively targeted by these compounds (Verstovsek, 2009).
The clinical trial results are consistent with our study, where we
observed a statistically significant reduction in spleen weight
and reduced erythroid precursor cell numbers in Jak2+/VF mice
treated with TG101348, but this was not associated with elimina-
tion of the MPN-initiating population. Although we cannot rule
out that treatment with a higher dose of TG101348 or for a longer
duration could potentially diminish or possibly even eliminate
the MPN-initiating population, we observed clear evidence of
differential sensitivity to JAK2 kinase inhibition in vivo between
different Jak2+/VF cellular compartments, with JAK2 selective
effects on Jak2+/VF progenitors as compared with Jak2+/VF
LSKs. Furthermore, our demonstration that Jak2V617F has
modest effects on LSK phenotype suggests that JAK2 inhibitors,
regardless of efficacy, dose, or treatment duration, are unlikely to
have a curative therapeutic index in JAK2V617F-mediated MPN.
The therapeutic eradication of MPN-initiating cells will require
insights into the differential molecular circuitry of normal and
JAK2V617F mutant stem cells. Maintenance of JAK2V617F
disease-initiating cells may require normal self-renewal path-
ways in a manner analogous to the dependence of CML stem
cells on the Wnt-b-catenin (Zhao et al., 2007) and Hedgehog
(Dierks et al., 2008; Zhao et al., 2009) signaling pathways.
However, unlike chronic-phase CML, which appears to be a
monoallelic neoplasm driven byBCR-ABL, there is accumulating
evidence that additional genetic lesions occur within the HSC
compartment of BCR-ABL-negative MPN. At least 50% patients
with a JAK2V617F-positive MPN transform to a JAK2V617F-
negative acute leukemia, suggesting that JAK2V617F may not
be the disease-initiating mutation in many cases of MPN (Camp-
bell et al., 2006; Theocharides et al., 2007). Recently, inactivating
acquired mutations in TET2 (Delhommeau et al., 2009), ASXL1
(Gelsi-Boyer et al., 2009), and IDH1/2 (Abdel-Wahab et al.,
2010; Green and Beer, 2010) have been identified in multipotent
MPN progenitors. CD34+ HSCs with mutations in TET2 in addi-
tion to the JAK2V617F mutation show an increased capacity
over JAK2V617F single mutant CD34+ HSCs to repopulatey recipients measured 2–3 weeks posttransplantation are also shown (mean ±
treated with TG101348 or vehicle.
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IDH1/2 mutations have been associated with leukemic transfor-
mation in MPN (Abdel-Wahab et al., 2010; Green and Beer,
2010), suggesting that these mutations may enhance HSC
self-renewal. Little is known about the function of TET2, but it
was recently shown that TET1 has an enzymatic function in
epigenetic regulation (Tahiliani et al., 2009). Identifying strategies
to target TET2 therapeutically in the HSC compartment will
require the development of preclinical genetic murine models
that integrate TET2 loss into the Jak2V617F context. Such
models will enable the interrogation of the therapeutic suscepti-
bilities of MPN alleles within different hematopoietic compart-
ments.
In conclusion, we report a Jak2V617F heterozygote knockin
mouse model that develops a MPN resembling human PV. We
found that the LSK compartment contained the MPN-initiating
cell population but that Jak2V617F had modest effects on the
size of the LSK compartment or its subpopulations and on cell
cycle, signal transduction, or gene expression of LSK cells.
Furthermore, in functional studies employing competitive repo-
pulation assays, Jak2V617F did not confer a significant compet-
itive advantage to the LSK compartment. Concordant with this,
the disease-initiating population was not eradicated with
therapeutic dosing of a JAK2 kinase inhibitor. This model will
be valuable in evaluating the curative potential of MPN therapies.
Effective elimination of MPN disease-initiating cells will require
insights into the differential molecular dependencies of normal
and JAK2V617F mutant HSCs.
EXPERIMENTAL PROCEDURES
Generation of Jak2V617F Knockin Mice
The Jak2V617F knockin construct was generated via the recombineering
method (Liu et al., 2003; Copeland et al., 2001) (see Supplemental Information
for full details). Exposure to Cre recombinase results in inversion of the mutant
exon followed by an excision reaction that removes the WT exon, one LoxP
site, and one LoxP511 site, fixing the inversion in place (Figure 1A). All results
described pertain to Jak2V617F germline expressing heterozygous mice. We
did not obtain any viable germline homozygous Jak2V617F-expressing
animals and as a result we believe germline homozygosity for Jak2V617F to
be embryonically lethal. We were unable to generate viable homozygous
floxed animals (Jak2Fl/Fl) because the targeting construct appeared to interfere
with WT Jak2 expression such that Jak2Fl/Fl functioned as a Jak2 null which is
known to be embryonically lethal (Parganas et al., 1998; Neubauer et al., 1998).
Heterozygous floxed mice (Jak2+/Fl) had no phenotype. All experiments were
conducted with an IUCAC-approved animal protocol at our institution.
Survival Analysis
Jak2+/VF or age-matched Jak2+/+ control mice were monitored biweekly and
were sacrificed when visibly ill (hunched posture, weight loss). Statistical
analysis was performed with Prism 5 software (GraphPad, San Diego, CA)
via the Kaplan-Meier method.
Histopathology
Tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and
stained with hematoxylin and eosin or with reticulin to assess for fibrosis.
Images of histological slides were obtained on a Nikon Eclipse E400 micro-
scope (Nikon, Tokyo, Japan) equipped with a SPOT RT color digital camera
model 2.1.1 (Diagnostic Instruments, Sterling Heights, MI).
Flow Cytometry
BM cells were isolated from age-matched littermates between 1 and 6 months
of age backcrossed to C57BL/6 and were flushed from hind leg bones with594 Cancer Cell 17, 584–596, June 15, 2010 ª2010 Elsevier Inc.PBS (GIBCO) + 2% FBS + penicillin/streptomycin (Cambrex, Biowhittaker),
lysed on ice with red blood cell (RBC) lysis solution (Puregene), and washed
in PBS (GIBCO) + 2% FBS. Single-cell suspensions of spleen were prepared
by pressing tissue through a cell strainer and lysed and washed in the same
manner as BM. Cells were stained with monoclonal antibodies in 2% FBS/
PBS for 30 min on ice.
ACCESSION NUMBERS
Gene expression data are available in GEO database with the accession
number GSE21842.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
(flow cytometry, megakaryocyte ploidy analysis, cytokine stimulation and
intracellular phosphoprotein analysis, cell cycle, colony-forming assays,
gene expression profiling, bone marrow transplantation, and JAK2 inhibitor
studies), four figures, and one table and can be found with this article online
at doi:10.1016/j.ccr.2010.05.015.
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